ZHONGSHENGYAOYE(SZ:002317) Sou Hu Cai Jing·2025-10-14 20:26Core Viewpoint - The company is actively pursuing international market opportunities and is focused on the commercialization of its innovative drugs, particularly the antiviral drug Anladiwei and the RAY1225 injection for obesity and type 2 diabetes treatment [2]. Group 1: Company Performance - As of October 14, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 16.56 yuan, down 1.02%, with a turnover rate of 3.3%, trading volume of 251,100 shares, and a transaction amount of 422 million yuan [1]. Group 2: Product Development and Market Strategy - The company is advancing the commercialization of Anladiwei, which has shown strong inhibitory activity against various strains of influenza viruses, including those resistant to existing treatments [2]. - The RAY1225 injection is in Phase III clinical trials, showing significant improvements in weight loss, blood sugar reduction, and various cardiovascular and metabolic risk factors compared to placebo [2]. - The company is also progressing with the Phase III clinical trial of Anladiwei granules for children, having received ethical approval [2]. Group 3: Market Dynamics and Investor Relations - On October 14, the net inflow of main funds was 4.27 million yuan, while speculative funds saw a net inflow of 9.01 million yuan, and retail investors experienced a net outflow of 13.29 million yuan [2]. - The company is closely monitoring the dynamics of disease outbreaks and is prepared for production and sales during the flu season [2]. - The company is actively engaging in negotiations for the inclusion of Anladiwei in the annual medical insurance directory to benefit more patients [2].